medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 1

<< Back Next >>

Ann Hepatol 2018; 17 (1)

Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease

Kobyliak N, Abenavoli L, Falalyeyeva T, Beregova T

Language: English
References: 36
Page: 153-161
PDF size: 366.14 Kb.


ABSTRACT

Introduction and aim. Today probiotics have been suggested as a treatment for the prevention of non-alcoholic fatty liver disease (NAFLD). Smectite is a natural silicate that binds to digestive mucous and has the ability to bind endo- and exotoxins. The present study was designed to determine whether probiotics plus smectite is superior to probiotic alone on the monosodium glutamate (MSG) induced NAFLD model in rats. Materials and methods. We included 60 rats divided into 4 groups 15 animals in each. Rats of group I were intact. Newborns rats of groups II-IV were injected with MSG. The III (Symbiter) group received 2.5 ml/kg of multiprobiotic “Symbiter” containing concentrated biomass of 14 probiotic bacteria genera. The IV (Symbiter+Smectite) groups received “Symbiter Forte” combination of probiotic biomass with smectite gel (250 mg). Results. In both interventional groups reduction of total NAS score as compared to MSG-obesity was observed. Indeed similar values of steatosis score (0.93 ± 0.22 vs. 0.87 ± 0.16) in both treatment groups, we observed that lower total score for Symbiter+ Smectite are associated with more pronounced reduction of lobular inflammation (0.13 ± 0.09 vs. 0.33 ± 0.15) as compared to administration of probiotic alone. This data accompanied with significant reduction of IL-1 and restoration of IL-10 between these 2 groups. Conclusions. Additional to alive probiotic administration of smectite gel due to his absorbent activity and mucus layer stabilization properties can impact on synergistic enhancement of single effect which manifested with reduction of lobular inflammation and at list partly steatohepatitis prevention.


REFERENCES

  1. Farrell GS, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatol 2006; 43: 99-112.

  2. Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, Terrault NA. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatol 2005; 41: 372-9.

  3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.

  4. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-71.

  5. Kobyliak N, Abenavoli L. The role of liver biopsy to assess non-alcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9: 159-69.

  6. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of nonalcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-49.

  7. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterol 1998; 114: 842-5.

  8. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatol 2010; 52: 1836-46.

  9. Mykhalchyshyn G, Kobyliak N, Bodnar P. Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Metab Disord 2015; 14: 44.

  10. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016: article in press, dx.doi.org/10.1016/ j.metabol.2015.12.012.

  11. Kobyliak N, Virchenko O, Falalyeyeva T. Pathophysiological role of host microbiota in the development of obesity. Nutr J 2016: 15: 43.

  12. Federico A, Dallio M, Godos J, Loguercio C, Salomone F. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res 2016: 167: 116-24.

  13. Kobyliak N, Conte C, Cammarota G, Haley AP, Styriak I, Gaspar L, Fusek J, et al. Probiotics in prevention and treatment of obesity: a critical view. Nutr Metab (Lond) 2016; 13: 14.

  14. Savcheniuk O, Kobyliak N, Kondro M, Virchenko O, Falalyeyeva T, Beregova T. Short-term periodic consumption of multiprobiotic from childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity. BMC Complement Altern Med 2014: 14: 247.

  15. Bailey SW. Summary of recommendations of AIPEA nomenclature committee on clay minerals. Clay Minerals 1980; 65: 1-7.

  16. Guarino A, Albano F, Ashkenazi S, Gendrel D, Hoekstra JH, Shamir R, Szajewska H. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008; 6: 619-21.

  17. Faure C. Role of Antidiarrhoeal Drugs as Adjunctive Therapies for Acute Diarrhoea in Children. Int J Pediatr 2013; 2013: 612403.

  18. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-72.

  19. Kobyliak N, Abenavoli L, Falalyeyeva T, Virchenko O, Natalia B, Beregova T, Bodnar P, et al. Prevention of NAFLD devel opment in rats with obesity via the improvement of pro/antioxidant state by cerium dioxide nanoparticles. Clujul Med 2016; 89: 229-35.

  20. Kondro M, Mykhalchyshyn G, Bodnar P, Kobyliak N, Falalyeyeva T. Metabolic profile and morpho-functional state of the liver in rats with glutamate-induced obesity. Curr Issues Pharm Med Sci 2013; 26: 379-81.

  21. Nakagawa T, Ukai K, Ohyama T, Gomita Y, Okamura H. Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. Exp Anim 2000; 49: 239-49.

  22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatol 2005; 41: 1313-21.

  23. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1956; 226: 497-509.

  24. Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez- Llorente C, Gil A. Probiotic Mechanisms of Action. Ann Nutr Metab 2012; 61: 160-74.

  25. Ritze Y, Bárdos G, Claus A, Ehrmann V, Bergheim I, Schwiertz A, Bischoff SC. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS One 2014; 9: e80169.

  26. Plaza-Diaz J, Gomez-Llorente C, Abadia-Molina F, Saez-Lara MJ, Campaña-Martin L, Muñoz-Quezada S, Romero F, et al. Effects of Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036 on hepatic steatosis in Zucker rats. PLoS One 2014; 9: e98401.

  27. Yin YN, Yu QF, Fu N, Liu XW, Lu FG. Effects of four Bifidobacteria on obesity in high-fat diet induced rats. World J Gastroenterol 2010; 16: 3394-401.

  28. Reichold A, Brenner SA, Spruss A, Förster-Fromme K, Bergheim I, Bischoff SC. Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model. J Nutr Biochem 2014; 25: 118-25.

  29. Cani PD, Van Hul M. Novel opportunities for next-generation probiotics targeting metabolic syndrome. Curr Opin Biotechnol 2015; 32: 21-7.

  30. Kobyliak N, Falalyeyeva T, Virchenko O, Mykhalchyshyn G, Bodnar P, Spivak M, Yankovsky D, et al. Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention. BMC Gastroenterol 2016; 16: 34.

  31. Dupont C, Vernisse B. Anti-diarrheal effects of diosmectite in the treatment of acute diarrhea in children: a review. Pediatric Drugs 2009; 11: 89-99.

  32. Weese JS, Cote NM, de Gannes RVG. Evaluation of in vitro properties of di-tri-octahedral smectite on clostridial toxins and growth. Equine Veterinary Journal 2003; 35: 638-41.

  33. Dahan R, Schatz B, Isal JP, Caulin C. Effects of smectite on the gastric difference induced by aspirin in man. Gastroenterol Clin Biol 1984; 8: 878-9.

  34. Faure C. Role of Antidiarrhoeal Drugs as Adjunctive Therapies for Acute Diarrhoea in Children. Int J Pediatr 2013; 2013: 12403.

  35. González R, de Medina FS, Martínez-Augustin O. Anti-inflammatory effect of diosmectite in hapten-induced colitis in the rat. Br J Pharmacol 2004; 141: 951-60.

  36. Mahraoui L, Heyman M, Plique O, Droy-Lefaix MT, Desjeux JF. Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-α. Gut 1997; 40: 339-43.




2020     |     www.medigraphic.com